Robustness of circadian rest-activity rhythm for predicting efficacy of intravenous cetuximab (Cet) and hepatic artery infusion (HAI) of chronomodulated irinotecan, 5-fluorouracil and oxaliplatin (Chrono-Optiliv) for liver metastases from colorectal cancer (LM-CRC) (Optiliv translational study, NCT00852228).
Abdoulaye Karaboué
No relevant relationships to disclose
Pasquale F. Innominato
No relevant relationships to disclose
Mohamed Bouchahda
No relevant relationships to disclose
Magali Mocquery
No relevant relationships to disclose
Rachel Bossevot
No relevant relationships to disclose
Virginie Plessis
No relevant relationships to disclose
Davina Bouchoucha
No relevant relationships to disclose
Rene Adam
No relevant relationships to disclose
Francis Levi
No relevant relationships to disclose